| |  Online-Ressource |
|---|
| Verfasst von: | Haist, Maximilian [VerfasserIn]  |
|---|
| | Stege, Henner [VerfasserIn] |
|---|
| | Lang, Berenice Mareen [VerfasserIn] |
|---|
| | Tsochataridou, Aikaterini [VerfasserIn] |
|---|
| | Salzmann, Martin [VerfasserIn] |
|---|
| | Mohr, Peter [VerfasserIn] |
|---|
| | Schadendorf, Dirk [VerfasserIn] |
|---|
| | Ugurel, Selma [VerfasserIn] |
|---|
| | Placke, Jan-Malte [VerfasserIn] |
|---|
| | Weichenthal, Michael [VerfasserIn] |
|---|
| | Gutzmer, Ralf [VerfasserIn] |
|---|
| | Leiter, Ulrike [VerfasserIn] |
|---|
| | Kaatz, Martin [VerfasserIn] |
|---|
| | Haferkamp, Sebastian [VerfasserIn] |
|---|
| | Berking, Carola [VerfasserIn] |
|---|
| | Heppt, Markus V. [VerfasserIn] |
|---|
| | Tschechne, Barbara [VerfasserIn] |
|---|
| | Schummer, Patrick [VerfasserIn] |
|---|
| | Gebhardt, Christoffer [VerfasserIn] |
|---|
| | Grabbe, Stephan [VerfasserIn] |
|---|
| | Loquai, Carmen [VerfasserIn] |
|---|
| Titel: | Response to first-line treatment with immune-checkpoint inhibitors in patients with advanced cutaneous squamous cell carcinoma |
|---|
| Titelzusatz: | a multicenter, retrospective analysis from the German ADOReg registry |
|---|
| Verf.angabe: | Maximilian Haist, Henner Stege, Berenice Mareen Lang, Aikaterini Tsochataridou, Martin Salzmann, Peter Mohr, Dirk Schadendorf, Selma Ugurel, Jan-Malte Placke, Michael Weichenthal, Ralf Gutzmer, Ulrike Leiter, Martin Kaatz, Sebastian Haferkamp, Carola Berking, Markus Heppt, Barbara Tschechne, Patrick Schummer, Christoffer Gebhardt, Stephan Grabbe and Carmen Loquai |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 11 November 2022 |
|---|
| Umfang: | 14 S. |
|---|
| Fussnoten: | Gesehen am 26.01.2023 |
|---|
| Titel Quelle: | Enthalten in: Cancers |
|---|
| Ort Quelle: | Basel : MDPI, 2009 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 14(2022), 22, Artikel-ID 5543, Seite 1-14 |
|---|
| ISSN Quelle: | 2072-6694 |
|---|
| Abstract: | Cutaneous squamous cell carcinoma (cSCC) is a common malignancy of the skin and has an overall favorable outcome, except for patients with an advanced stage of the disease. The efficacy of checkpoint inhibitors (CPI) for advanced cSCC has been demonstrated in recent clinical studies, but data from real-world cohorts and trial-ineligible cSCC patients are limited. We retrospectively investigated patients with advanced cSCC who have been treated with CPI in a first-line setting at eight German skin cancer centers registered within the multicenter registry ADOReg. Clinical outcome parameters including response, progression-free (PFS) and overall survival (OS), time-to-next-treatment (TTNT), and toxicity were analyzed and have been stratified by the individual immune status. |
|---|
| DOI: | doi:10.3390/cancers14225543 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/cancers14225543 |
|---|
| | Volltext: https://www.mdpi.com/2072-6694/14/22/5543 |
|---|
| | DOI: https://doi.org/10.3390/cancers14225543 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | advanced cutaneous squamous cell carcinoma |
|---|
| | cemiplimab |
|---|
| | checkpoint inhibitor therapy |
|---|
| | immunosuppression |
|---|
| | real-world data |
|---|
| | response durability |
|---|
| K10plus-PPN: | 1832506339 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Response to first-line treatment with immune-checkpoint inhibitors in patients with advanced cutaneous squamous cell carcinoma / Haist, Maximilian [VerfasserIn]; 11 November 2022 (Online-Ressource)
